CD1d–invariant natural killer T cell receptor (CD1d-iNKT TCR)

The CD1d–invariant natural killer T (iNKT) cell receptor complex is a specialized immune axis that bridges innate and adaptive immunity. CD1d is a non-polymorphic, MHC class I-like molecule that presents lipid and glycolipid antigens, rather than peptides, to a unique subset of T cells known as iNKT cells (Brossay et al., 1998, J Exp Med). These cells express a semi-invariant T-cell receptor (TCR) that recognizes these lipid-CD1d complexes with high specificity. Upon recognition of an agonist like alpha-galactosylceramide, iNKT cells rapidly produce a diverse array of cytokines, including IFN-gamma and IL-4, which can activate natural killer cells, dendritic cells, and B cells (Borg et al., 2007, Nature). This interaction is a significant therapeutic target in oncology, where iNKT activation is leveraged to enhance anti-tumor immunity, and in vaccine development, where glycolipids act as potent adjuvants (Giaccone et al., 2002, J Clin Oncol). However, therapeutic application is challenged by the potential for iNKT cell anergy and the risk of systemic cytokine-related toxicities (Exley et al., 2017, Clin Cancer Res).

Other names

CD1d-iNKT complexCD1d-iNKT axisCD1d-restricted T-cell receptorVα24-Jα18 TCRInvariant natural killer T cell receptor

Agonist-induced activation of invariant natural killer T (iNKT) cells through the presentation of glycolipid antigens by the CD1d molecule to the semi-invariant T-cell receptor, leading to rapid cytokine release and downstream immune modulation (Bendelac et al., 2007, Annu Rev Immunol).